Printer Friendly

Global Breast Cancer Therapeutics 2015: Pipeline Market Analysis to 2023.

DUBLIN, Oct. 22, 2015 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/2cr7j9/breast_cancer) has announced the addition of the "Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" report to their offering.

Based on clinical phases, the breast cancer therapeutics: pipeline analysis market has been segmented into three major categories: phase I drug candidates, phase II drug candidates, and phase III drug candidates.

Tabular representation for phase I drug candidates and phase II drug candidates has been provided, which summarizes information about promising drug candidates under clinical trials and associated conditions, sponsors and collaborators, primary outcome measure, time frame, and status about designated safety issue.

The phase III drug candidates section is further differentiated into various key molecules that are expected to give promising results. These molecules include Palbociclib (PD-0332991) + Fulvestrant, NK105, BKM120, NKTR-102, Neratinib, Olaparib, DOXIL, ABP 980, CT-P6, and Trastuzumab Emtansine + Pertuzumab.

Commercial analysis for all these molecules is provided by forecasting the anticipated market revenue from the expected year of commercialization until 2023. Compound annual growth rate (CAGR %) for each of these molecules is also provided for the period from the expected commercialization year to 2023.

A list of recommendations has been provided for new entrants as well as existing market players to assist in taking strategic initiatives in a bid to establish a strong pipeline for breast cancer therapeutic drugs. The report also profiles major players in the breast cancer therapeutics: pipeline analysis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and Sanofi.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Market Overview

Chapter 4 Global Breast Cancer Therapeutics: Pipeline Analysis, by Drugs (Phase III)

Chapter 5 Recommendations

Chapter 6 Company Profiles

- AstraZeneca plc

- Eisai Co., Ltd.

- Eli Lilly and Company

- F. Hoffmann-La Roche Ltd.

- GlaxoSmithKline plc

- Novartis International AG

- Pfizer, Inc.

- Sanofi

For more information visit

http://www.researchandmarkets.com/research/2cr7j9/breast_cancer

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:Oct 22, 2015
Words:502
Previous Article:Facial Recognition Market 2015 - Global Industry Analysis to 2022 for the $1.3 Billion Industry.
Next Article:Behind the Wheel, episode 1: the New Holland tractor that could change the face of sustainable farming.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters